Hướng dẫn 6 cách đăng ký 4G Viettel ngày cực rẻ, dùng thả ga
Sana Biotechnology Announces the Acceptance of Four
SEATTLE, March 14, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that four abstracts, including a late-breaking abstract, highlighting preclinical data from both the hypoimmune and fusogen platforms have been accepted for poster presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting taking place April 14-19, 2023 in Orlando, FL.
Late-breaking poster details:
Title: | Increased potency of CD8-targeted fusosomes enhances CAR gene delivery to resting primary T cells |
Session Title: | Late-Breaking Research: Experimental and Molecular Therapeutics 3 |
Session Date: | Wednesday, April 19, 2023 |
Session Time: | 9:00 a.m. - 12:30 p.m. ET |
Location: | Poster Section 35 |
Abstract Number: | LB311 |
Poster details:
Title: | Modulation of resting T cell status to enhance transduction and CAR T expansion following exposure to CD8-targeted fusosomes |
Session Category: | Experimental and Molecular Therapeutics |
Session Title: | Gene and Vector-based Therapy |
Session Date: | Monday, April 17, 2023 |
Session Time: | 1:30 p.m. - 5:00 p.m. ET |
Location: | Poster Section 16 |
Abstract Number: | 2734 |
Title: | Development of a novel, fully human anti-CD19 chimeric antigen receptor for in vivo delivery via CD8-targeted fusosome |
Session Category: | Experimental and Molecular Therapeutics |
Session Title: | Gene and Vector-based Therapy |
Session Date: | Monday, April 17, 2023 |
Session Time: | 1:30 p.m. - 5:00 p.m. ET |
Location: | Poster Section 16 |
Abstract Number: | 2735 |
Title: | Engineered hypoimmune CAR T cells provide lasting tumor control in immunocompetent allogeneic humanized mice even with re-challenge |
Session Category: | Immunology |
Session Title: | CAR T-cell Therapy 2 |
Session Date: | Tuesday, April 18, 2023 |
Session Time: | 9:00 a.m. - 12:30 p.m. ET |
Location: | Poster Section 23 |
Abstract Number: | 4091 |
Full regular abstracts and late-breaking abstract titles are available for viewing via the AACR Online Itinerary Planner located here: https://www.abstractsonline.com/pp8/#!/10828. Late-breaking abstract text will be posted to the AACR Online Itinerary Planner and Meeting App on Friday, April 14, 2023 at 12:00 p.m. ET.
About Sana Biotechnology
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, Cambridge, South San Francisco, and Rochester. For more information about Sana Biotechnology, please visit https://sana.com/.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including those related to the Company’s vision, progress, and business plans; expectations for the Company’s participation at the 2023 American Association for Cancer Research Annual Meeting; expectations for the Company’s presentations at such meeting, including the content of such presentations; and expectations for the publication of abstracts. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Company’s strategy, expectations, cash runway and future financial condition, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would,” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company’s current and future research and development programs, preclinical and clinical trials, as well as the economic, market and social disruptions due to the ongoing COVID-19 public health crisis. For a detailed discussion of the risk factors that could affect the Company’s actual results, please refer to the risk factors identified in the Company’s SEC reports, including but not limited to its Quarterly Report on Form 10-Q dated November 2, 2022. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.
Investor Relations & Media:
Nicole Keith
investor.relations@sana.com
media@sana.com
TIN LIÊN QUAN
Tango Therapeutics to Highlight Preclinical Data on
BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced the acceptance of two oral and two poster...
Mablink Bioscience to Present Promising Preclinical Data
Mablink Bioscience to Present Promising Preclinical Data for Lead ADC Candidate MBK-103 at the AACR Annual Meeting 2023 In vivo antitumor efficacy with...
Beam Therapeutics to Participate in the 43rd Annual Cowen
CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic...
Lyra Therapeutics Announces Appointment of John Bishop,
WATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the Company or Lyra), a clinical-stage biotechnology company...
Molecular Partners to Present at SVB Leerink Global
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage...
REE Automotive, Ltd. Announces Date for Fourth Quarter 2022
TEL-AVIV, Israel, March 09, 2023 (GLOBE NEWSWIRE) -- REE Automotive, Ltd. (NASDAQ: REE) (“REE” or the “Company”), an automotive technology company and...
THỦ THUẬT HAY
Nguyên nhân và 5 cách khắc phục tình trạng loa điện thoại bị nhỏ cực hiệu quả mà bạn nên thử ngay
Loa điện thoại bị nhỏ trong quá trình sử dụng là do nguyên nhân nào gây ra? Hãy cùng tìm hiểu cách khắc phục tình trạng này cực đơn giản trong bài viết.
Hướng dẫn sử dụng một số tính năng tiện ích trên Windows 10
Nhiều lúc khi sử dụng Windows 10, bạn ít nhiều gặp các quảng cáo gây cản trở công việc hoặc thấy vướng mắt. Hãy cùng FPTShop tìm cách tắt những quảng cáo này đi
Cách vô hiệu hóa tính năng tự động đọc văn bản PDF trên Chrome, Firefox
PDF hiện nay đã có thể được đọc một cách tự động trên các trình duyệt. Tuy nhiên, nếu không muốn sử dụng thì các bạn có thể vô hiệu hóa tính năng này.
Pin iPhone 6s dùng được bao lâu?
Nếu bạn đang băn khoăn về thời lượng pin của chiếc iPhone 6s liệu có đáp ứng nhu cầu sử dụng của bạn hay không. Hôm nay, chúng tôi sẽ phần nào giải đáp.
Cài đặt Windows Timeline Support trên trình duyệt Chrome, Firefox và Vivaldi
Về cơn bản, Windows Timeline là tính năng hỗ trợ, nó tạo ra các snapshot của ứng dụng, web hay bất cứ chương trình nào mà người dùng đã sử dụng và khôi phục trong thời gian 30 ngày.
ĐÁNH GIÁ NHANH
Đánh giá sơ bộ iPhone X: một bước tiến lớn về mặt phần cứng
Sau nhiều tháng chờ đợi, chúng ta cuối cùng đã có được iPhone X để trải nghiệm thực sự. Apple cho biết đó là một sản phẩm để kỷ niệm 10 năm sau cuộc cách mạng mà họ tạo ra trong mảng kinh doanh điện thoại trên thế giới.
Trên tay Huawei MediaPad M3 2017: 7 triệu, chưa xuất sắc nhưng đủ dùng và đáng tiền
MediaPad M3 2017 được đóng hộp đơn giản, bao da tặng kèm được đóng gói riêng. Hộp của M3 bao gồm củ sạc 5V-2A, que chọc sim, sách HDSD, cáp microUSB và không có tai nghe đi kèm. Tuy nhiên, theo thông tin, nếu đặt hàng
So sánh Honda CR-V 5+2 và Mazda CX-5: Lựa chọn nào phù hợp với bạn?
Câu hỏi trên có lẽ cần nhiều năm bán hàng để khẳng định. Và khi trong phân khúc compact SUV ngày càng phát triển thì cả hai mẫu xe gia đình tiêu biểu trên đều xứng đáng được lựa chọn.